Reston, VA (September 30, 2021)—PSMA (prostate-specific membrane antigen) PET/CT is more accurate than conventional CT in the detection of hepatocellular carcinoma metastases, according to research published in the September issue of The Journal of Nuclear Medicine. PSMA PET imaging was also found to be associated with a change of management for nearly half of the patients, allowing them to receive the most effective treatment for their disease.
Hepatocellular carcinoma—a type of liver cancer—is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Despite the availability of a growing number of local and systemic therapies, patient survival remains short. Accurate staging is critical for management decisions.
“With more accurate imaging for staging of patients, we can identify early on patients who could benefit from particular treatments, like chemotherapy, which has an impact on survival and quality of life,” said Nader Hirmas, MD, physician scientist at the department of nuclear medicine at Essen University Hospital in Essen, Germany.
Hepatocellular carcinoma is typically diagnosed with conventional imaging, like CT or MRI. Recent research, however, has shown that hepatocellular carcinoma has PSMA on the surface of its cancer cells. To explore this discovery, study authors assessed the impact of PSMA PET imaging on patients with hepatocellular carcinoma and compared it to CT.
The retrospective study included 40 patients who received imaging with 68Ga-Ga-PSMA-11 PET/CT. Patients received a CT as well as a PSMA PET scan. Three blinded nuclear medicine physicians determined the presence of hepatocellular carcinoma in the liver and elsewhere in the body based on the CT images and the PSMA PET images separately, and lesions were validated by follow-up imaging or biopsy. Researchers then compared the detection rates for each imaging modality, as well as changes made in staging, grouping and management plans of patients.
Results indicate that PSMA PET and CT are similar in diagnosing hepatocellular carcinoma in the liver, but that PSMA PET is more accurate for tumors that have spread beyond the liver. With a more accurate diagnosis of the locations of the hepatocellular carcinoma tumors, the original management plan changed in 19 of the 40 patients—almost half of the patient sample—leading towards a shift towards systemic therapy.
“We hope that this study encourages more research into the topic, so that multi-disciplinary oncology practices and guidelines would use PSMA PET in the diagnosis of hepatocellular carcinoma,” noted Wolfgang Fendler, MD, vice chair of nuclear medicine at the Essen University Hospital in Essen, Germany. “More broadly, it shows that many of the molecular imaging techniques could supplement or even outperform conventional imaging in the diagnosis of particular tumors.”
This study was made available online in January 2021 ahead of final publication in print in September 2021.
The authors of “68Ga-Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma” include Nader Hirmas, Miriam Sraieb, Francesco Barbato, Michael Nader, Justin Ferdinandus, Christoph Rischpler, Ken Herrmann, Pedro Fragoso Costa, Manuel Weber and Wolfgang P. Fendler, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; Catherine Leyh and Heiner Wedemeyer, Department of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; and Benedikt M. Schaarschmidt and Lale Umutlu, Institute of Diagnostic and Interventional Radiology and Neuroradiology; University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or firstname.lastname@example.org.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 11 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal of Nuclear Medicine
Method of Research
Subject of Research
68Ga-Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma
Article Publication Date
Ken Herrmann reports personal fees from Bayer, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, and ymabs, as well as personal and other fees from Sofie Biosciences, nonfinancial support from ABX, and grants and personal fees from BTG, all of which are outside the submitted work. Christian M. Lange has received speaker and consultancy fees from Abbvie, MSD, Roche, Eisai, Behring, Falk, Novartis, and Norgine, all of which are outside the submitted work. Manuel Weber is on the Speakers Bureau for Boston Scientific. Wolfgang P. Fendler is a consultant for Endocyte and BTG, and he received personal fees from RadioMedix, Bayer, and Parexel, as well as financial support from Mercator Research Center Ruhr (MERCUR, An-2019-0001), IFORES (D/107-81260, D/107- 30240), Doktor Robert Pfleger-Stiftung, and Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg, all of which are outside the submitted work.